- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05716945
The OPTIMISE Study
Optimized Immunosuppression for Corneal Transplantation: A Multi-center Randomized Controlled Clinical Trial
Rationale:
The cornea is the most transplanted tissue in the Netherlands, with more than 1,500 procedures performed each year. A minimally invasive technique called Descemet Membrane Endothelial Keratoplasty (DMEK) has become the preferred method in the past decade. The main advantage of DMEK over previous techniques is a low graft rejection rate (1-2% per year). Despite this, rejection prophylaxis after DMEK follows the same high potency regimen as previous techniques in the first year, and patients are burdened with indefinite immunosuppression. The current project, OPTIMISE, aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects.
Corticosteroid eye drops are the mainstay of ocular immunomodulatory therapy. Their main side effect is a steroid-induced increase in intraocular pressure (IOP). It manifests in about one-fourth of patients within the first year after surgery and can lead to irreversible optic nerve damage and vision loss. Patients with IOP elevation require additional medications and hospital visits resulting in reduced quality of life and increased costs. The optimal dosing regimen in the first year after DMEK and whether patients may safely stop steroids after one year remains unknown. As a result, protocols in the Netherlands vary considerably from surgeon to surgeon. Patients are potentially over-treated in the short and long-term, resulting in undue burden for the patient and increased costs. Consequently, the Dutch Ophthalmology Society (NOG) identified the optimal short- and long-term immunosuppressive protocol for corneal transplantation as one of its Top 10 knowledge gaps, underscoring relevance for clinical practice. With this work, the investigators expect to address this knowledge gap to the benefit of our patients and society.
Objective:
The OPTIMISE study aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. The hypothesis of this study is that Fluorometholone 0.1% in the first year and discontinuing medication in the second year is a cost-effective treatment strategy after DMEK.
Study design:
The design of this study is a randomized, controlled multicentre trial with a duration of 24 months.
Study population:
The study population will consist of 342 patients aged 21 years or older undergoing DMEK surgery in one eye.
Intervention:
All patients will receive Descemet's Membrane Endothelial Keratoplasty. Following this procedure, patients will be randomized into the following post-operative regime in two stages:
STEP-I (Year 1):
Control group: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
Intervention group: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.
STEP-II (Year 2):
Control Group: Half the patients in each study arm will use FML 0.1% daily. Intervention Group: Half the patients in each study arm will discontinue steroids.
Main study parameters/endpoints:
Primary outcomes:
Step-I: IOP elevation compared to baseline Step-II: Endothelial cell loss (ECL) compared to pre-surgical baseline
Secondary outcomes are:
- Rejection free graft survival.
- Patient reported outcome measures.
- Incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE)
- Structural outcomes including corneal, central macular and retinal nerve fibre layer thicknesses, and optic nerve head imaging.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sharista P.G. Baidjnath Panday, MD
- Phone Number: +31 6 40186513
- Email: sharista.baidjnath.panday@mumc.nl
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 21 years or older registered on the NOTR as candidates for DMEK corneal transplantation
Exclusion Criteria:
- Inability to complete follow up or comply with study procedures
- Previous corneal graft in the study eye
- Known sensitivity or contraindication to the ingredients in the study medications
- History of uveitis or herpetic keratitis
- Human Leukocyte Antigen (HLA) typed allograft
- Pregnancy (current and planned) or lactation
- Use of other local or systemic immunosuppressive drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention STEP I (Year 1 after DMEK)
|
Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. Year 2: Half the patients in each study arm will use FML 0.1% daily.
Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
|
ACTIVE_COMPARATOR: Control STEP I (Year 1 after DMEK)
|
Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
|
EXPERIMENTAL: Intervention STEP II (Year 2 after DMEK)
|
Half the patients in each study arm will discontinue steroids.
|
ACTIVE_COMPARATOR: Control STEP II (Year 2 after DMEK)
|
Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. Year 2: Half the patients in each study arm will use FML 0.1% daily. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference of intraocular pressure elevation between the two arms
Time Frame: Year 1
|
Year 1
|
Difference of endothelial cell loss (ECL) compared to pre-surgical baseline between arms
Time Frame: Year 2
|
Year 2
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference of rejection free graft survival between arms
Time Frame: 1-2 years
|
1-2 years
|
Differences of patient reported outcome measures between groups
Time Frame: 1-2 years
|
1-2 years
|
Differences of incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE)
Time Frame: 1-2 years
|
1-2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Genetic Diseases, Inborn
- Eye Diseases, Hereditary
- Corneal Diseases
- Corneal Dystrophies, Hereditary
- Fuchs' Endothelial Dystrophy
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anti-Allergic Agents
- Dexamethasone
- Fluorometholone
Other Study ID Numbers
- 2022-500109-41-00
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraocular Pressure
-
University of PittsburghRecruiting
-
The University of Hong KongCompleted
-
Rajiv Gandhi Cancer Institute & Research Center...CompletedIntraocular PressureIndia
-
Prince of Songkla UniversityCompletedIntraocular PressureThailand
-
Astellas Pharma IncCompletedIntraocular PressureUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Icare Finland OyCompleted
-
Iladevi Cataract and IOL Research CenterCompleted
Clinical Trials on Fluorometholone 0.1% Oph Susp
-
Massachusetts Eye and Ear InfirmaryLondon School of Hygiene and Tropical Medicine; University of Pennsylvania; The... and other collaboratorsActive, not recruitingEye Diseases | Eyelid Diseases | Trichiasis | Trachomatous Trichiasis (TT) | TrachomatousEthiopia
-
University Hospital of PatrasCompleted
-
Actavis Inc.Completed
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
University of PennsylvaniaLions Club International Foundation; Berhan Public Health and Eye Care Consultancy... and other collaboratorsCompletedTrachoma | Trichiasis | Bilamellar Tarsal RotationEthiopia
-
Cairo UniversityCompletedIntraocular PressureEgypt
-
L.V. Prasad Eye InstituteAllerganRecruitingCongenital Hereditary Endothelial Dystrophy of CorneaIndia
-
University of UtahCompletedCorneal Opacity | Intraocular PressureUnited States
-
Prism Vision GroupCompleted
-
Cindy HutnikGlaucoma Research Society of CanadaUnknown